Biblio
Differences in cellular composition of peripheral blood stem cell grafts from healthy stem cell donors mobilized with either G-CSF alone or G-CSF and Plerixafor. Biol Blood Marrow Transplant. 2018.
Role of Donor Clonal Hematopoiesis in Allogeneic Hematopoietic Stem-Cell Transplantation. J Clin Oncol. 2018:JCO2018792184.
Modified DHAP regimen in the salvage treatment of refractory or relapsed lymphomas. J Cancer Res Clin Oncol. 2019.
. Immunogenetics in stem cell donor registry work: The DKMS example (Part 2). Int J Immunogenet. 2020.
Stem cell donor registry activities during the COVID-19 pandemic: a field report by DKMS. Bone Marrow Transplant. 2020.
CCR5Δ32 mutations do not determine COVID-19 disease course. Int J Infect Dis. 2021.
. Genetics of HLA peptide presentation, and impact on outcomes in HLA-matched allo-HCT. Transplant Cell Ther. 2021.
Allogeneic hematopoietic stem cell transplantation in patients aged 60-79 years in Germany (1998-2018): a registry study. Haematologica. 2023.
Immune Surveillance of Acute Myeloid Leukemia Is Mediated by HLA-Presented Antigens on Leukemia Progenitor Cells. Blood Cancer Discov. 2023:OF1-OF22.
The role of anti-thymocyte globulin in allogeneic stem cell transplantation (HSCT) from HLA-matched unrelated donors (MUD) for secondary AML in remission: a study from the ALWP /EBMT. Bone Marrow Transplant. 2023.
Unsupervised meta-clustering identifies risk clusters in acute myeloid leukemia based on clinical and genetic profiles. Commun Med (Lond). 2023;3(1):68.
Donor genotype based outcome prediction after allogeneic stem cell transplantation: no land in sight. Front Immunol. 2024;15:1350470.
Harmonizing definitions for hematopoietic recovery, graft rejection, graft failure, poor graft function, and donor chimerism in allogeneic hematopoietic cell transplantation: a report on behalf of the EBMT, ASTCT, CIBMTR, and APBMT. Bone Marrow Transplant. 2024.
Providing hematopoietic stem cell products from unrelated donors to the world: DKMS donor centers and DKMS Registry. Best Pract Res Clin Haematol. 2024;37(1):101541.
. Smart Conditioning with Venetoclax-Enhanced Sequential FLAMSA + RIC in Patients with High-Risk Myeloid Malignancies. Cancers (Basel). 2024;16(3).